For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...
How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes ...
It’s hard to know how long anxiety disorders will last when you’re in the thick of them. It was during the mid-2000s that my ...
Is it anxiety or a panic attack? Discover the key differences and learn why understanding them matters for managing your ...
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 m ...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 ...
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...
The emergency department, while sophisticated and able to treat a variety of medical issues, is not always equipped to ...
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback